Brief: Ceapro Commences Patient Enrollment In First-In-Human Clinical Study Assessing Beta Glucan As A Cholesterol-Lowering Agent
03/06/2019 14:15
June 3 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC. COMMENCES PATIENT ENROLLMENT IN FIRST-IN-HUMAN
CLINICAL STUDY ASSESSING BETA GLUCAN AS A CHOLESTEROL-LOWERING
AGENT
Source text for Eikon: ID:nGNX6LhS6W
Further company coverage: CZO.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases